Search 

New VC focused on biotech

Crossject, publicly traded on the Paris exchange, has developed a proprietary, needle free auto-injector (ZENEO®) which enables the intuitive intramuscular or subcutaneous administration of pre-filled injectable drugs in less than 1/10th of a second, in only two steps (open, push on the injection site).
Crossject will commercialize, its proprietary, clinically proven needle free auto-injector through partners, a portfolio of rescue drug-device combinations, for example Epinephrine in anaphylactic shock, Midazolam in epileptic seizure, Terbutaline in severe asthma exacerbation, or Hydrocortisone in adrenal crisis.
Our innovative needle-free drug delivery based portfolio could be a great fit with your emergency care positioning. I would like to introduce you to the ZENEO® key benefits and learn more about your Licensing-in strategy and how we might work together.

CureMeta is a therapeutic oncology biotech with the mission to develop therapeutic antibodies to novel cancer targets that are present in aggressive cancers and to develop new powerful cancer drugs to provide meaningful treatments and cures for patients with metastatic cancer.

We are seeking partners to out-license our lead therapeutic: CM-09, a first in class Antibody-Drug-Conjuate for gastric cancers.

Dyadic International, Inc. is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, based on a patented and proprietary genetically modified strain of the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), to address opportunities in the human and animal health markets. C1 is a potentially game-changing biopharmaceutical gene expression platform that may help bring biologic vaccines, drugs and other biologic products to market faster and more efficiently than existing expression platforms, such as Chinese hamster ovary (CHO) cells, E. coli, yeast and baculovirus in greater volumes, at lower cost and with new properties that can improve access and cost to patients and the healthcare system.